Latest news

• NICE broadens access to Alexion's rare disease drug Strensiq

  New deal offers NHS England a discount for the drug. More babies with the rare and life-threatening disease paediatric-onset hypophosphatasia (HPP) will be able to get access to ... There are up to seven cases of HPP diagnosed every year in England, and

• AZ, BMS and Boehringer among UK Prix Galien finalists

  asfotase alfa. Strensiq. Alexion. paediatric-onset hypophosphatasia (HPP) - bone manifestations. Real World Evidence Award 2016 finalists.

• Alexion's rare bone disorder therapy rejected by NICE

  The National Institute for Health and Care Excellence (NICE) has said evidence for the drug's benefits in paediatric-onset hypophosphatasia (HPP) - a rare, inherited disorder of the bones - is not ... pain. There are around seven cases of HPP diagnosed

• Ten new medicines recommended in Europe

  David Hallal, CEO of Alexion, said: “The CHMP positive opinions for Strensiq and Kanuma are significant milestones in bringing these therapies to infants, children, and adults suffering from HPP and ... Both Strensiq and Kanuma are highly innovative

• Alexion expands in Ireland with new biofacility

  It is however hoping to add a second from its own stable later this year - Strensiq (asfotase alfa) for hypophosphatasia (HPP) - as well as Kanuma (sebelipase alfa) for lysosomal acid lipase